InvestorNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Focused on Recreating Mid-Market REE Supply Chain in North America
April 5, 2023
Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) is engaged in the exploration for and separation and scalable production of rare earth elements (“REEs”) in Canada and the U.S. The company is out to ensure that China’s dominance in REE production and processing does not leave vulnerable those North American companies that are particularly reliant on […]
InvestorNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Positioning as REE Thought Leader
March 29, 2023
Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a company developing specialized rare earth element (“REE”) separation and processing solutions, is playing a role in reasserting North America’s independence in tech resource mining. “The company is preparing to demonstrate its proprietary RapidSX(TM) process for the low-cost separation and purification of REEs through an accelerated form of […]
InvestorNewsBreaks – Why Progressive Care Inc. (RXMD) Is ‘One to Watch’
March 24, 2023
Progressive Care (OTCQB: RXMD) is an organization based in Florida that, through its wholly owned subsidiaries PharmcoRx Pharmacy and ClearMetrX, offers personalized care services and technology to support the managed health care industries. “Progressive Care offers a wide range of innovative solutions to address the dispensing, delivery, dosing and reimbursement of clinically intensive, high-cost drugs. […]
InvestorNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Positioned to Promote US Self-Sustainability, Creation of North American REE Supply Chain
March 15, 2023
Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a company engaged in the separation and scalable production of rare earth metals (“REE”) in the U.S. and Canada, is focused on providing best-in-class metal separation products and services to the mining and mineral extraction industries. “To date, China has been the dominant leader in providing REE for […]
InvestorNewsBreaks – Ucore Rare Metals Inc.’s (TSX.V: UCU) (OTCQX: UURAF) RapidSX(TM) Combining Time-Proven SX with New Platform to Process REEs
March 10, 2023
Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) is engaged in the exploration for and separation and scalable production of rare earth elements (“REEs”) in Canada and the U.S. The company is disrupting China’s dominance with its near-term processing facility in Louisiana, subsequent Strategic Metals Complexes (“SMCs”) in Alaska and Canada, and longer-term development of Boken […]
InvestorNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Focused on Bringing Best-in-Class Products to Market
March 3, 2023
Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF) is pursuing the exploration, separation and scalable production of rare earth elements (“REE”) in Canada and the U.S. “Ucore Rare Metals is focused on becoming a leading advanced technology company that provides best-in-class metal separation products and services to the mining and mineral extraction industry. Through strategic partnerships, […]
InvestorNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Working to Provide Best-in-Class Metal Separation Products and Services
February 17, 2023
Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a company focused on rare earth element (“REE”) resource development and precious metal commercialization, recently provided an update on the commissioning process for its RapidSX(TM) Demonstration Plant for the separation of heavy and light REEs. “Ucore’s vision includes becoming a leading advanced technology company that provides the best-in-class […]
InvestorNewsBreaks – Why Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Is ‘One to Watch’
February 8, 2023
Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), headquartered in Halifax, Nova Scotia, is engaged in rare earth element (“REE”) resource development and in commercializing its critical metals separation technology, RapidSX(TM). “The company is guided by principles of environmental, social and corporate governance (‘ESG’) with a focus on disrupting China’s current dominance of the U.S. REE […]
InvestorNewsBreaks – BioNxt Solutions Inc. (CSE: BNXT) (OTCQB: XPHYF) (FSE: 4XT) to Expand Portfolio with Precision Drug Delivery Technology
December 12, 2022
BioNxt Solutions (CSE: BNXT) (OTCQB: XPHYF) (FSE: 4XT) today announced that it has signed a non-binding term sheet for the acquisition of certain intellectual property assets and rights related to a novel solid oral drug dosage form coating delivery technology. “BioNxt is extremely pleased to expand our technology portfolio with an additional drug delivery platform,” […]
InvestorNewsBreaks – BioNxt Solutions Inc. (CSE: BNXT) (OTCQB: XPHYF) (FSE: 4XT) Holds Key Meetings, Advances Product at Frankfurt CPHI Conference
November 21, 2022
BioNxt Solution (CSE: BNXT) (OTC: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery and diagnostic and new active pharmaceutical ingredient investment opportunities, is reporting on its participation at the CPHI pharma conference in Frankfurt, Germany. Earlier this month, BioNxt management attended the event, which is the largest pharma conference in the world; […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Changes Name to BioNxt Solutions Inc.
November 10, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) has announced a name change. According to the company, effective next Monday, Nov. 14, 2022, the company’s name will change from XPhyto Therapeutics Corp. to BioNxt Solutions Inc. Along with the name change, the company’s trading symbol will change to BNXT from XPHY. The company will continue to focus […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Major Milestone on Path to Commercialization of Lead Product
October 18, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today reported the results of its Rotigotine transdermal (“TDS”) patch human skin cadaver study and dissolution data. The company’s Rotigotine patch is based on the TDS platform technology developed by Vektor Pharma TF GmbH, its wholly owned German subsidiary. Further to its product update on Oct. 11, […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Completion of Rotigotine TDS Patch Study
October 11, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today provided a product development report on its Rotigotine transdermal (“TDS”) patch. According to the update, the company’s Rotigotine patch is based on TDS platform technology developed by its wholly owned German subsidiary, Vektor Pharma TF GmbH. The company has, over the past 90 days, been focused […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Inks LOI to Identify Manufacturing, Strategic Business Opportunities
October 5, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) has signed a nonbinding letter of intent (“LOI”) with a U.S.-based thin film manufacturing firm. The collaboration between the two companies will focus on evaluating potential business synergies for manufacturing, import/export, distribution and product development. According to the announcement, the manufacturing firm has a state-of-the-art, FDA-certified pharma production […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE:4XT) Announces Patent Application for Novel Psychedelic Compound Library
September 20, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE:4XT) has filed a patent application covering a significant library of novel psychedelic compounds. According to the announcement, each compound included in the filing is designed to provide specific alterations in their respective biopharmaceutical properties. The company noted that it expects the global psychedelic drugs market to see significant market […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Exploring Expanded Application of ODF Screening Tests
July 18, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE:4XT) is taking a close look at a significant potential market for its oral dissolvable (“ODF”) biosensor screening tests for oral inflammation. According to the company, some buprenorphine medicines prescribed to treat opioid use disorder (“OUD”) and pain have been linked to serious oral health problems that necessitate medical intervention. […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Congratulates Dr. Raimar Loebenberg as Recipient of 2022 CSPS Award
June 27, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today congratulated Prof. Dr. Raimar Loebenberg as the 2022 recipient of the CSPS Award of Leadership in Canadian Pharmaceutical Sciences. Dr. Loebenberg, a director and founder of XPhyto, is a professor in the Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta (“UoA”) and the founder and […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Expands European Team to Add Pharmaceutical Manufacturing Expert
June 8, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) today announced that Dr. Florian A. Sahr has joined its European operations as head of project management. A German-born and internationally trained leader in formulation, technology transfer and new-product manufacturing, Dr. Sahr has a strong track record of drug development. This includes transdermal (“TDS”) and oral dissolvable […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Reports Positive Results of Rotigotine Transdermal Patch Study
May 9, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has released an update on its Rotigotine transdermal (“TDS”) patch. The patch is based on the TDS platform technology developed by the company’s wholly owned German subsidiary, Vektor Pharma TF GmbH. The company noted that it had […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Provides Update on Market, Product Development of Key Biosensor
April 12, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has released a market and product development report. The report focused on XPhyto’s sublingual oral dissolvable film (“ODF”) biosensor development pipeline, which include the company’s oral dissolvable products. These products are based on proprietary ODF platform technology […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Update on Rotigotine Transdermal Patch Development
April 4, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, is reporting on the market and product development of its Rotigotine transdermal (“TDS”) patch, which is designed for the treatment of Parkinson’s disease (“PD”) and restless legs syndrome (“RLS”). XPhyto’s Rotigotine patch features the TDS platform technology […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Closes First Tranche of Private Placement
April 1, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has announced that, further to its news release of March 25, 2022, it has closed the first tranche of its private placement. According to the update, the company issued 1,250,000 common […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Updates on Psychedelic Medicine Programs Progess, Novel Compounds Milestone
February 22, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has released an update regarding its wholly owned subsidiary XPhyto Laboratories Inc. XPhyto Labs’ psychedelic medicine programs are focused on a multipronged approach to psychedelic medicine and include GMP (“GMP”) drug synthesis, proprietary drug-delivery systems, novel psychedelic […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Issues Update Regarding Its Three Primary Business Divisions
February 8, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, today issued an update as part of its product development, commercialization and revenue growth strategy. The company reported on its three business divisions and wholly owned subsidiaries, which include Vektor Pharma […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces New Covid-ID Lab Sales Contracts
February 1, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has executed Covid-ID Lab sales contracts with Corona Testzentren (Digitallife), powered by digitallifecare GmbH, Germany. According to the announcement, Digitallife runs several coronavirus test centers south of Stuttgart, Germany, servicing some 75,000 area residents. XPhyto noted that […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Provides Update on Integration of 3a-diagnostics GmbH
January 24, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, today provided an update on the integration of 3a-diagnostics GmbH (“3a”) into XPhyto’s German operations. According to the update, the acquisition of 3a, announced Dec. 6, 2021, is a primary driver […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Appoints European Head of Sales
January 18, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has named Drahoslav Zdarek as its head of sales in Europe. According to the announcement, Zdarek will focus on developing distribution, sales and marketing of the company’s products; top on the list of assignments Zdarek will be […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Inks Czech Republic Distribution Deal, Announces Rollout Plan for Additional European Territories
January 13, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has signed a distribution agreement with TechUnit s.r.o. (Limited). TechUnit is a privately owned company focused on medical product distribution, advertisement and promotion. The agreement outlines parameters for the distribution of XYPHY’s Covid-ID Lab in the Czech […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Strategic Appointments
January 10, 2022
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, today announced two key appointments to continue its focus on research, development and commercialization of its biosensor and diagnostic products, including for the detection of COVID-19. Roland Spleiss, a seasoned commercial […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces January 2022 Commencement of Epilepsy Clinical Trial
December 15, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, today provided an update on the development of its fast-dissolving CBD oral strips. With significant complexities involved in the planning and preparation for the pending pilot trial, the company announced that […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Completes Transformative Step in Commercial Strategy with 3a Acquisition
December 6, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has completed its acquisition of 3a-diagnostics GmbH (“3a”), first announced July 20, 2021. “The strategic acquisition of 3a is a transformative step in XPhyto’s commercial strategy,” said Peter Damouni, XPhyto director. […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Appoints New CFO
November 22, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has named a new chief financial officer: Joseph Meagher. A chartered professional accountant (“CPA, CA”) and a chartered director, Meagher most recently worked at Defence Therapeutics Corp, a publicly traded biotechnology company engineering next-generation vaccines and anti-body […]
Q4 Investor Summit Small Cap & Micro Cap Conference To Offer Opportunity to Meet with C-level Management of 90+ Companies
November 15, 2021
Virtual: November 16 – 17, 2021 Small and Micro-cap investors are invited to attend the Q4 Investor Summit being held on November 16-17, 2021. The event is organized by the Investor Summit Group, recognised as a highly reputed brand for hosting North America’s largest independent investor conferences. Over 90 presenting companies from a wide spectrum […]
XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) Featured in Coverage of Investor Summit Group’s Q4 Virtual Event
November 10, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Shares Drug-Development Update
October 12, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, has released updated information regarding its drug formulation and development focus. The company is continuing its focus on advancing multiple generic and hybrid-generic programs for neurotherapeutics. Highlights of the update include that planning for XPhyto’s Rotigotine transdermal […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Extends Agreements with Partners
October 11, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, announced that it has extended its investor relations consulting agreement with Knox Communications Inc. (“KCI”) and M. Davis & Associates Capital Inc. The agreements are designed to support XPhyto in its marketing and investor communications activities. The […]
XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured in Coverage of Benzinga’s Healthcare Small Cap Conference
September 27, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is a bioscience accelerator focused on next-generation drug diagnostics, delivery and new active pharmaceutical ingredient investment opportunities, including: rapid, low-cost infectious disease test (EU approved rapid PCR test) and oral health screening tests; precision transdermal and oral dissolvable drug formulations; and standardization of emerging active pharmaceutical ingredients for neurological applications, including […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Proprietary COVID-19 PCR Test COVID-ID Lab Launch Deemed a Success
September 8, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, announced that the market launch of its 25-minute COVID-19 PCR Test COVID-ID Lab has been a success. The company unveiled the project at test centers in Berlin, and XPhyto reports the successfully optimization of operational procedures and […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Registers First Oral Disease Biosensor for Commercialization
August 30, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, announced that it has registered its first biosensor test in oral inflammation with German authorities. The company registered the easy, at-home, self-check test with the assistance of its partner and acquisition target, 3a-diagnostics GmbH (“3a”). The biosensor […]
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured in “Forbes” Article Discussing Mescaline
August 13, 2021
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, was featured in an article titled “Is Mescaline a Key Component in the Future of Medicine? XPhyto Aims to Find Out.” The article notes that mescaline (3,4,5-trimethoxyphenethylamine), the magical alkaloid found in the peyote cactus and similar […]